Genital Warts caused by HPV – treatment, recurrence, research 2018

What should you know about genital warts caused by HPV?

Anogenital warts typically develop approximately 2–3 months after HPV infection (almost all caused by types 6 or 11); however, not all persons infected with HPV types 6 and 11 develop genital warts. Anogenital warts should be assessed by a clinician and can be treated, although many warts (20–30%) regress spontaneously. Recurrence of anogenital warts within 3 months is common (approximately 30%), whether clearance occurs spontaneously or following treatment.

Read the whole manual about HPV and genital warts:

https://www.cdc.gov/vaccines/pubs/surv-manual/chpt05-hpv.html

What is the most effective treatment against genital warts?

The most effective treatment (with the lowest recurrences) is called Photodynamic Therapy. Unfortunately this treatment is not available in the Western world. I mean: it is possible to get Photodynamic Therapy against i.e. ACNE on face, but it’s not possible to get it against genital warts. Why? I have no idea. Maybe it is a some kind of conspiracy? Anyway the fact is one: HPV virus hides in the skin, and it is possible to eradicate it during a few ALA-PDT treatments.

There were many clinical trials about Photodynamic therapy, but usually in China. You can check this PDF file:

https://www.cdc.gov/std/tg2015/evidence-tables/hpvtableevidence-genitalwarts-2015.pdf

What is the biggest problem with genital warts?

The biggest problem with genital warts is that they can come back, especially in the first months after their show up. All available methods (Cryotherapy, Podophyllotoxin, Aldara, Veregen…) have high recurrence rates.

What can you do to lower genital warts recurrence rate?

You can take medicinal mushrooms to boost your immune system (for example:  Coriolus versicolor and Reishi had 88% clearance rate after 2 months, during one clinical trial).

You can try food supplements like Ellagic Acid and Annona Muricata extract.  In one clinical trial EA+AM gave 74% HPV clearance rate after 6 months.

You can try use Panavir gel topically. Panavir is an antiviral medicine created in Russia. It works antiviral and immunostimulating. There are many russian clinical trials about its effectiveness.

http://poi555.com/2018/01/panavir-from-russia-alternative-treatment-for-hpv-and-genital-warts/

You can try hypethermia (44-45 celsius degree) on your genitals, but it might be hard to get this treatment in any clinic.

You can combine removing warts with taking Inosine Pranobex (3g daily for 4 weeks).

If you have strong recurrences – you should check your glucose level in blood. If you have diabetes, then you should know that there is correlation between the strength of HPV/number of recurrences and diabetes.

So what can you do?

Option A:

You can go to China and try to get Photodynamic Therapy (ALA-PDT) against genital warts. That’s the most expensive option.

Option B:

You can try Cryotherapy or Podophyllotoxin, and be mentally prepared for recurrences.

Option C:

You can try Cryotherapy or Podophyllotoxin, and 1 immune-booster (i.e. medicinal mushrooms, Ellagic acid + Annona Muricata extract)

Option D:

You can try Cryotherapy or Podophyllotoxin, 1 immune-booster and – topically – Panavir gel. Panavir gel should be applied 2 times daily (5 days before the treatment, 10 days after the treatment).

YOU CAN BUY PANAVIR AT OTC ONLINE STORE

Option E:

Combine Cryotherapy or Podophyllotoxin with Inosine Pranobex: 3g daily (1g in the morning/afternoon/evening) for 4 weeks. If you do this, then the chances for recurences are as low as 6-7%.

What about ALDARA?

If you are a man, then it’s a total waste of time.
If you are a woman, then you can try it (it has 60% effectiveness in females).

What about ACV, Thuja, homeopathic medicines?

Forget about it. It’s your health. Don’t waste your time on methods without any clinical trials. You can check Google Scholar and search for clinical trials.

Panavir from Russia – alternative treatment for HPV and genital warts

Panavir – biologically active substance of Panavir is ”GG17” – plant polysaccharide, relating tohexose glycoside class. It main dosage form – intravenous solution 0,004% in 5 ml ampoules (single therapeutic dose). Additional dosage form: rectal suppositories, vaginal suppositories, gel for outward application. Preparation has original pharmacologic property, non-toxic in therapeutic dose (LD50 ~ 3000 therapeutic dose). It is successfully used where ordinary antiviral preparations are not effective or contraindicative or have unsatisfactorily effect: chronic tick-borne encephalitis, ophthalmoherpes, herpes zoster (shingles), cytomegalovirus, Epstein-Barr virus, Human papilloma virus. Now Panavir tests for treatment chronic hepatitis B and C.

Biologically active substance of Panavir is ”GG17” – plant polysaccharide from Solanum tuberosum. GG17 is a high-molecular hexose glycoside with complex structure: Glucose (38,5%), Galactose (14,5%), Rhamnose (9%), Mannose (2,5%), Xylose (1,5%), Uronic acid (3,5%).

Preparation was developed by the company National Research Company jointly with Research Institute of Physicochemical Medicine, Ministry of Health and Social Development of the Russian Federation, under the direction of the academician of RAMS Sergienko V.I.

CLINICAL STUDY 1

This research is devoted to determination of the clinical efficacy of Panavir in the combined therapy of the uterine cervix diseases associated with human papillomavirus (HPV). The article presents data of the complex examination of 59 patients. Patients with diagnosed 16th, 18th, 31st, 33rd types of HPV underwent destructive methods of treatment of the cervix followed by Panavir. The efficacy of Panavir was estimated by PCR in 3, 6 and 12 months from the beginning of treatment and it was 84,7%. Antiviral therapy permits to prevent recurrence of papillomavirus infection of the cervix uteri.

http://journals.rudn.ru/medicine/article/view/3463

CLINICAL STUDY 2

All the patients were given Panavir rectal suppositories in a daily dose of 200 mg for 10 days. Radio waves were used to destroy anogenital warts in Group 1 patients. The patients were examined using laboratory monitoring immediately and 30, 60, and 90 days after therapy. Results. Following 3 months of Panavir therapy in combination with radio wave mass destruction, human papillomavirus DNA was not detected in 80% of the patients; remission was recorded in 90%. After 3 months of Panavir use, 85% of the patients with latent infection were found to cease human papillomavirus DNA excretion. Conclusion. The high clinical efficacy of Panavir suppositories permits one to recommend the agent in this formulation for wide practical application.

EBSCO

CLINICAL STUDY 3

The article presents the results of treatment of 51 men with recurrent genital HPV infection in the form of genital warts. Patients were divided into two groups depending on the treatment. Group 1 of patients has received the combination treatment–electrocoagulation + pharmacotherapy (panavir intravenously and topically in the form of a gel), Group 2 of patients–only electrocoagulation. According to the results of follow-up within 6 months, disease recurrence rate was significantly higher in Group 2–39.5% versus 9.6% in the Group 1. Postoperative complications were also more frequently recorded in the Group 2. These findings suggest that the combined treatment of reccurent forms of genital warts is preferred than just using destructive methods of treatment.

https://www.ncbi.nlm.nih.gov/pubmed/24649765

CLINICAL STUDY 4

The efficiency of combined therapy in patients with HPV-associated chronic endocervitis was investigated. The antiviral preparation modulating immune response (panavir) was used. The results showed that panavir increases the efficiency of therapy and eliminates the HPV in 96,6% of patients.

ResearchGate

CLINICAL STUDY 5

The results of combination therapy were comparatively analyzed in 60 patients with human papillomavirus (HPV)-associated cervical neoplasias. Thirty patients in the study group were given the antiviral and immunomodulatory drug – intravenous and intravaginal panavir before destructive treatment. Thirty patients in the control group had traditional destructive treatment. It has been ascertained that the use of systemic and local combination antiviral therapy before destructive treatments enhances the efficiency of the therapy performed, promotes a reduction in process relapsing, and leads to HPV elimination in 85% of cases.

https://elibrary.ru/item.asp?id=18911191

IMPORTANT:

I found informations about Panavir when I was searching for clinical trials about HPV and genital warts. I have learned that Panavir is very effective in combined therapy. It lowers recurrences of genital warts and increase the speed of HPV clearance.

I think that the best approach is combined therapy: Cryotherapy (or Podophyllotoxin) to remove genital warts, and Panavir gel to avoid recurrences.

If you want,  YOU CAN BUY PANAVIR AT OTC ONLINE STORE.

HPV การรักษาโรคติดเชื้อเอชพีวี – ทำอย่างไรที่จะรักษาให้หายเร็วขึ้น?

ไมใช่เพียงการรักษาเชื้อเอชพีวีแต่เป็นการต่อสู้ไวรัส

ทำอย่างไรที่จะหายจากเชื้อเอชพีวีอย่างรวดเร็ว?

1) งดสูบบุหรี่
2) งดดื่มแอลกอฮอล์
3) เช็คระดับน้ำตาล (กลูโคส)ในเลือด เนื่องจากมีผลทำให้เกิดหูด ถ้าหากคุณได้รับเชื้อไวรัสเอชพีวี6/11 และเป็นโรคเบาหวาน
4) รับประทานอาหารที่ดีต่อสุขภาพ ทานผักเยอะๆ
5) ลดการบริโภคน้ำตาลและคาร์โบไฮเดรต เพราะว่ามะเร็งและเชื้อเอชพีวีชอบน้ำตาล
6) ออกกำลังกายอย่างน้อย 2-3 ครั้งต่อสัปดาห์
7) รับประทานอาหารเสริมหรือสารสกัดจากเห็ด
– เห็ดอวิ๋นจือ เสริมสร้างระบบภูมิคุ้มกัน
– เห็ดหลินจือ ต่อสู้ทำลายกับเชื้อเอชพีวีและเซลล์มะเร็งโดยตรง
– เห็ดหอม ยับยั้งการเจริญเติบโตของหูด

ข้อสำคัญ : ซื้อเฉพาะสารสกัดเห็ดหลินจือ หรือน้ำสกัดเห็ดหลินจือเท่านั้น จึงจะออกฤทธิ์ดีที่สุด หลีกเลี่ยงการใช้ผงเห็ดซึ่งไม่มีฤทธิ์รักษษโรค

ยกตัวอย่างวิธีทาน:
– รับประทาน เห็ดอวิ๋นจือ3-4 กรัม หลังอาหาร ในตอนเช้า
– รับประทาน เห็ดหลินจือ 1-2 กรัม ในตอนเย็น

8) ฉีดวัคซีนต้านเชื้อเอชพืวี ซึ่งไม่ได้ช่วยอะไรหากคนติดเชื้อแล้ว แต่สามารถต่อต้านเชื้อเอชพีวีสายพันธุ์อื่น วัคซีนที่ดีที่สุด กราดาซิล (Gardasil) และ กราดาซิล 9

ทำอย่างไรไม่ให้เกิดหูด?

แนะนำทดลองใช้:
– Podophyllotoxin ยาโพโดฟิลโลทอกซิน ฤทธิ์ต่อต้านการแบ่งตัวของเซลล์ แต่สามารถติดเชื้อได้อีก
– Imiquimod/Aldara ยาอิมิควิโมดหรืออัลดารา ใช้เป็นยาที่กระตุ้นภูมิคุ้มกันต้านทานโรคของร่างกายให้ตอบสนองต่อการเจริญเติบโตที่ผิดปกติของผิว ซึ่งอาจจะเห็นผลช้า
– Veregen เวเรเจน เป็นสารสกัดจากชาเขียว ให้ผลสัมฤทธิ์ดี ใช้เวลานานจึงจะเห็นผมและมีราคาแพง

ปรึกษาหรือสอบถามคุณหมอที่ดูแลคุณ
– การจี้ด้วยไฟฟ้า ซึ่งจะระคายเคืองและแสบบริเวณที่จี้
– การรักษาด้วยการยิงเลเซอร์
– การบำบัดด้วยความเย็นจัด เห็นผลเร็วและราคาถูก
– โฟโต้ไดนามิค เทอราปี เป็นกระบวนการใช้แสงกระตุ้นการออกฤทธิ์ของสารละลายชนิดพิเศษที่ทาลงบนผิว เป็นการเร่งปฏิกิริยาเคมี ต่อต้านการเกิดหูด

โดยสรุปวิธีที่ดีที่สุดในการรักษาเอชพีวี
– เช็คระดับน้ำตาล (กลูโคส) และหลีกเลี่ยงอาหารจั๊งค์ฟู้ด
– ทานผลิตภัณฑ์ตัวยาที่ทำจากเห็ด

เพิ่มเติมจากที่ได้กล่าวไว้แล้ว เพื่อกำจัดหูดออกไป
– ใช้ ยาโพโดฟิลโลทอกซิน สำหรับบริเวณหูดตุ่มเล็กๆ
– ใช้การบำบัดด้วยความเย็นจัดกำจัดหูดขนาดใหญ่
– ทดลองใช้โฟโต้ไดนามิค เทอราปี

Natural HPV treatment: Ellagic acid and Annona Muricata – strong antiviral herbs

It seems that we have a new natural treatment for HPV infections.

Journal of Functional Foods published article “Antiviral activity of Ellagic acid and Annona Muricata in cervical HPV related pre-neoplastic lesions: A randomized trial” about Ellagic acid and Annona Muricata, two natural ingredients that fights with HPV virus:

Ellagic acid (EA) and Annona Muricata (AM) have antioxidant, anticarcinogenic and antiviral activity demonstrated by in vitro models. This pilot study investigated the in vivo potential anti-viral activity in women affected by Low squamous intraepithelial lesion (L-SIL) related to high risk human papilloma virus (HR-HPV), and the ability to modify the oncoproteins expression in the cervical lesion thickness. Sixty women affected by HR-HPV related L-SIL, were randomly divided into two groups: group A (n = 30) supplemented with EA (16 mg) + AM (100 mg) 2 times daily for 6 months and group B (n = 30) administered with placebo. HR-HPV clearance was obtained in 74% of cases in group A compared to 25% of cases in group B (p = 0.001) and p21 expression in LSIL thickness increased in 63.2% of cases in group A compared to 20% in group B (p = 0.03). AE/AM supplementation significantly induces HR-HPV elimination and stimulates p21 expression in LSIL thickness.

See the whole article:

http://www.sciencedirect.com/science/article/pii/S1756464617303225

So as for now we have at least 2 very effective natural treatments for HPV:
– mushroom extracts from Coriolus Versicolor + Reishi, 88% clearance after 2 months
– Ellagic acid and Annona Muricata, 74% clearance after 6 months

More informations about ellagic acid:

Ellagic acid is a Polyphenol compound found in numerous fruits and vegetables, including, raspberries; strawberries; cranberries; walnuts; pecans; pomegranates; and other plant foods. It is often regarded as an antioxidant. Ellagic Acid Clinical Tests on cultured human cells also show that Ellagic acid prevents the destruction of the p53 gene by cancer cells. Additional studies suggest that one of the mechanisms by which Ellagic acid inhibits mutagenesis and carcinogenesis is by forming adducts with DNA, thus masking binding sites to be occupied by the mutagen or carcinogen.

https://pubchem.ncbi.nlm.nih.gov/compound/ellagic_acid#section=Top

Remember to use EXTRACTS because they have high amounts of active ingredients.

The Strongest Antiviral Mushrooms: Reishi and Chaga – HPV treatment 2018

Reishi mushroom extracts contains such active ingredients as:
– polysaccharides
– triterpenes

Chaga mushroom extracts contains such active ingredients as:
– polysaccharides
– triterpenes
– betulinic acid

Remember to use ONLY WATER EXTRACTS or ALCOHOL EXTRACTS. Avoid “powdered mushrooms” – you can’t digest chitin and – even if – they have very, very little active ingredients.

Antioxidant polysaccharides

Polysaccharides from mushrooms including Pleurotus eryngii, P. ostreatus, P. nebrodensis, Lentinus edodes, Hypsizygus marmoreus, Flammulina velutipes, Ganoderma lucidum, and Hericium erinaceus were isolated by water extraction and alcohol precipitation. Our results suggest that all tested polysaccharides have the significant antioxidant capacities of scavenging free radicals (1,1-diphenyl-2-picrylhydrazyl and hydroxyl radicals). Among them, the H. erinaceus polysaccharide exhibits the highest 1,1-diphenyl-2-picrylhydrazyl radical-scavenging activity, whereas the L. edodes polysaccharide shows the strongest scavenging ability for hydroxyl radicals. Furthermore, using the MCF-7 breast cancer cell line and HeLa cells, all 8 selected polysaccharides are able to inhibit the proliferation of tumor cells, but the strength of inhibition varied depending on the mushroom species and the concentration used. Notably, G. lucidum polysaccharide shows the highest inhibition activity on MCF-7 cells. By comparison, H. erinaceus polysaccharide has the strongest inhibitory effect on HeLa cells. Moreover, high-performance liquid chromatography with a carbohydrate analysis column showed significant differences in polysaccharide components among these mushrooms. Thus our data suggest that the different species of mushrooms have the variable functions because of their own specific polysaccharide components. The 8 mushroom polysaccharides have the potential to be used as valuable functional food additives or sources of therapeutic agents for antioxidant and cancer treatments, especially polysaccharides from H. erinaceus, L. edodes, and G. lucidum.

http://dl.begellhouse.com/journals/708ae68d64b17c52,7b35b5ed6bb0a817,0d63c11a3ff8f73e.html

Reishi  (Ganoderma lucidum) vs. HPV

This preliminary randomized study investigated the efficacy of medicinal mushrooms, Trametes versicolor (TV), Ganoderma lucidum (GL), and Laetiporus sulphureus (LS), on the clearance of oral human papillomavirus (HPV, serotypes 16 and 18). Among 472 patients who underwent oral swabs for gingivitis, 61 patients were positive for HPV16 or HPV18. Twenty patients were included in group 1 (LS) and 41 patients were included in group 2 (TV+GL) for 2 months. Polymerase chain reaction (PCR) for HPV was performed at inclusion and after 2 months. In group 1, the clearance was equal to 5% after 2 months of treatment. In group 2, the clearance was equal to 88% (P<0.001). The detection of HPV16 or HPV18 could become relevant in routine since positivity is frequent and because a harmless and costless treatment may exist. The use of TV+GL for the clearance of oral HPV deserves further investigation.

http://dl.begellhouse.com/journals/708ae68d64b17c52,266d4152107fca7a,3512deba5cc9e72b.html

Reishi vs. bacteria

This article presents a comparative gas chromatography (GC)−mass spectrometry (MS)−based metabolomic analysis of mycelia and fruiting bodies of the medicinal mushroom Ganoderma lucidum. Three aqueous extracts−mycelia, fruiting bodies, and a mixture of them−and their sequential fractions (methanolic and ethyl acetate), prepared using an accelerated solvent extractor, were characterized by GC-MS to determine volatile organic compounds and by high-performance thin-layer chromatography to quantify ascorbic acid, a potent antioxidant. In addition, these extracts and fractions were assessed against Candida albicans and C. glabrata biofilms via the XTT reduction assay, and their antioxidant potential was evaluated. Application of chemometrics (hierarchical cluster analysis and principal component analysis) to GC data revealed variability in volatile organic compound profiles among G. lucidum extracts and fractions. The mycelial aqueous extract demonstrated higher anti-Candida activity and ascorbic acid content among all the extracts and fractions. Thus, this study illustrates the preventive effect of G. lucidum against C. albicans and C. glabrata biofilms along with its nutritional value.

http://dl.begellhouse.com/journals/708ae68d64b17c52,32c8651274405055,16650dfe7395ce6b.html

Reishi vs. cancer

In this study, we investigated the effects of the aqueous extracts of Lingzhi or Reishi medicinal mushroom, Ganoderma lucidum, obtained from three localities (China; and Morelos and Michoacan, Mexico) on cervical cells transformed by human papillomavirus (HeLa and SiHa) and C-33A cancer cells. The cells were plated in DMEM medium supplemented, and were incubated in the presence of different concentrations of G. lucidum for 24 h. Cell proliferation was determined by MTT colorimetric assay and viability by trypan blue assay. Inhibitory dose was determined (IC50) of the three different extracts of G. lucidum in the culture cell lines mentioned above. The apoptosis process was confirmed by nuclear DNA fragmentation and the cell cycle was determined by flow cytometry. The results showed that aqueous extracts G. lucidum obtained from three localities produced inhibition in the proliferation of VPH transformed cells; they also induced apoptosis and cell cycle arrest in HeLa, SiHa, and C-33A cancer cells. Therefore, it was found that aqueous extracts G. lucidum obtained from three different locations produced inhibitory effect on cancer cells and may have a potential therapeutic use for the prevention and treatment of this disease.

http://dl.begellhouse.com/journals/708ae68d64b17c52,3fd456332214676c,029d31540328ce6b.html

Reishi vs. tumors

Ganoderma lucidum has been established to be an antitumor natural product. Hot-water extracts of the mycelium of G. lucidum (GLP) exhibited antitumor effect against fibrosarcoma in male and female C3H mice and inhibited the metastasis of the tumor to the lung. Moreover, we have fractionated GLP into polysaccharide fraction [GLP(AI)] and nonpolysaccharide fraction. We found that GLP(AI) is the major component to show the in vivo antitumor effect on fibrosarcoma growth in C3H mice. The effect of PS-G purified from GLP(AI) by Sephadex and ion-exchange column chromatography on the induction of differentiation in leukemic U937 cells was examined. We found that it could stimulate blood mononuclear cells to secrete cytokines, TNF-a, IFN-g, IL-1b, and IL-6, etc., which were both antiproliferative and differentiation-inductive to the leukemic U937 and HL-60 cells. TNF-a and IFN-g, especially, induced apoptosis and differentiation in the treated leukemic cells. Furthermore, antitumor activity of G. lucidum on intraperitioneally implanted Lewis lung carcinoma in syngeneic C57BL/6 mice was investigated. The results showed that GLP significantly increased the lifespan of tumor-implanted mice, when administered intraperioneally alone or in combination with cytotoxic antitumor drugs (adriamycin, fluorouracil, thioguanine, methotrexate, or cisplatin) or a synthetic immunomodulator (imexon). The GLP was not cytotoxic to cultured cells, and the antitumor activity was abolished by pretreatment of mice with cyclosporine. These observations suggest that GLP exerts its antitumor effect mainly through immunopotentiation of the tumor-bearing animals.

http://dl.begellhouse.com/journals/708ae68d64b17c52,58cadf0c6c913237,1af485045b17e424.html

Betulinic acid from Chaga mushrooms

Betulinic Acid is a pentacyclic lupane-type triterpene derivative of betulin (isolated from the bark of Betula alba, the common white birch) with antiinflammatory, anti-HIV and antineoplastic activities. Betulinic acid induces apoptosis through induction of changes in mitochondrial membrane potential, production of reactive oxygen species, and opening of mitochondrial permeability transition pores, resulting in the release of mitochondrial apogenic factors, activation of caspases, and DNA fragmentation. Although originally thought to exhibit specific cytotoxicity against melanoma cells, this agent has been found to be cytotoxic against non-melanoma tumor cell types including neuroectodermal and brain tumor cells.

https://pubchem.ncbi.nlm.nih.gov/compound/betulinic_acid#section=Top

Chaga vs. cancer

The natural compound betulinic acid shows potent anticancer activity through activation of the mitochondrial pathway of apoptosis in cancer cells. Betulinic acid may also be used in combination protocols to enhance its antitumor activity, for example with chemo- or radiotherapy or with the death receptor ligand TRAIL. Because of its relative selective cytotoxicity against malignant compared to normal cells, betulinic acid is a promising new experimental anticancer agents for the treatment of human cancers.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658785/

Maitake (Grifola frondosa) vs. cancer

Maitake D (MD)-Fraction is a highly purified soluble β-glucan derived from Grifola frondosa (an oriental edible mushroom). Intraperitoneal (i.p.) injection of MD-Fraction has been reported to inhibit tumor growth via enhancement of the host immune system. In this study, we demonstrated that oral administration of MD-Fraction as well as i.p. injection significantly inhibited tumor growth in murine tumor models. After oral administration, MD-Fraction was not transferred to the blood in its free form but was captured by antigen-presenting cells such as macrophages and dendritic cells (DCs) present in the Peyer’s patch. The captured MD-Fraction was then transported to the spleen, thereby inducing the systemic immune response. Our study showed that MD-Fraction directly induced DC maturation via a C-type lectin receptor dectin-1 pathway. The therapeutic response of orally administered MD-Fraction was associated with (i) induced systemic tumor-antigen specific T cell response via dectin-1-dependent activation of DCs, (ii) increased infiltration of the activated T cells into the tumor and (iii) decreased number of tumor-caused immunosuppressive cells such as regulatory T cells and myeloid-derived suppressor cells. Our preclinical study suggests that MD-Fraction is a useful oral therapeutic agent in the management of patients with cancer.

In summary, our results demonstrated that orally administered MD-Fraction inhibits tumor growth by (i) inducing the systemic tumor-antigen specific T cell response via the dectin-1 dependent activation of DCs, (ii) increasing the infiltration of the activated T cells into the tumor and (iii) decreasing tumor-linked immunosuppressive elements such as Tregs and MDSCs. Our preclinical study advocates the implementation of MD-Fraction as an oral therapeutic agent in the management of patients with cancer.

http://onlinelibrary.wiley.com/doi/10.1002/ijc.27999/full

Medicinal mushrooms: Reishi / Linghzi vs. Hepatitis B, cancer, tumors, inflammation

Reishi vs. Hepatitis B

The polysaccharide fractions and triterpenes isolated from Ganoderma lucidum have shown protection effects on the liver in animal studies. This double-blind, randomised, and multicentered study aimed to evaluate the safety and effect of a G. lucidum extraction, Ganopoly, in chronic hepatitis B. Ninety patients with chronic hepatitis B, hepatitis В viral (HBV) DNA positivity, and aminotransferase elevation were included in this multicenter prospective randomized Phase I/II study. Patients were randomized to be given Ganopoly (n = 60) or placebo (n = 30) for 12 weeks, then followed up for 13 weeks. Effect of therapy on levels of HBV DNA and aminotransferase activities in serum and hepatitis В е antigen (HBeAg) status were investigated. There were 78 assessable patients who entered the trial for efficacy and safety; 13 of 52 (25%) patients receiving Ganopoly responded by reducing HBeAg and HBV DNA, compared to 1 of 26 (4%) in the control group (P < 0.05). Among those with serum aspartate aminotransferase (AST) values < 100 U/L (n = 29), 41% (12/29) responded, and among those with AST values > 100 U/L (n = 23), 65% (15/23) responded. Within the 6-month study period, 33% (17/ 52) of treated patients had normal aminotransferase (ALT) values, and 13% (7/52) had cleared hepatitis B surface antigen (HBsAg) from serum, whereas none of the controls had normal ALT values or had lost HBsAg. Eight of 60 patients in Ganopoly group and 4 of 30 in the controls were unable to be followed up due to loss or withdrawal. Our study indicates that Ganopoly is well tolerated and appears to be active against HBV in patients with chronic hepatitis B.

http://www.dl.begellhouse.com/journals/708ae68d64b17c52,72e968661ff5d957,09001a9418679e96.html

Reishi vs. Hepatitis B (II)

Herbal medicines are always considered to be a safe and useful approach for the treatment of chronic hepatopathy. Ganoderma luciudm (Curt.:Fr.) P. Karst. [(Ling Zhi, Reishi mushroom) (Aphyllophoromycetideae)], a highly ranked medicinal mushroom in Oriental traditional medicine, has been widely used for the treatment of chronic hepatopathy of various etiologies. Data from in vitro and animal studies indicate that G. lucidum extracts (mainly polysaccharides or triterpenoids) exhibit protective activities against liver injury induced by toxic chemicals (e.g., CCl4) and Bacillus Calmette-Guerin (BCG) plus lipopolysaccharide (LPS). G. lucidum also showed anti–hepatitis B virus (HBV) activity in a duckling study. Recently, a randomized placebo-controlled clinical study showed that treatment with G. lucidum polysaccharides for 12 weeks reduced hepatitis B e antigen (HBeAg) and HBV DNA in 25% (13/52) patients with HBV infection. The mechanisms of the hepatoprotective effects of G. lucidum have been largely undefined. However, accumulating evidence suggests several possible mechanisms. These include antioxidant and radical-scavenging activity, modulation of hepatic Phase I and II enzymes, inhibition of b-glucuronidase, antifibrotic and antiviral activity, modulation of nitric oxide production, maintenance of hepatocellular calcium homeostasis, and immunomodulating effects. G. lucidum could represent a promising approach for the management of various chronic hepatopathies. Further studies are needed to explore the kinetics and mechanisms of action of G. lucidum constituents with hepatoprotective activities.

http://www.dl.begellhouse.com/journals/708ae68d64b17c52,3389befb6be7818a,3ea891d772a09d0f.html

Reishi vs. tumors

Ganoderma lucidum has been established to be an antitumor natural product. Hot-water extracts of the mycelium of G. lucidum (GLP) exhibited antitumor effect against fibrosarcoma in male and female C3H mice and inhibited the metastasis of the tumor to the lung. Moreover, we have fractionated GLP into polysaccharide fraction [GLP(AI)] and nonpolysaccharide fraction. We found that GLP(AI) is the major component to show the in vivo antitumor effect on fibrosarcoma growth in C3H mice. The effect of PS-G purified from GLP(AI) by Sephadex and ion-exchange column chromatography on the induction of differentiation in leukemic U937 cells was examined. We found that it could stimulate blood mononuclear cells to secrete cytokines, TNF-a, IFN-g, IL-1b, and IL-6, etc., which were both antiproliferative and differentiation-inductive to the leukemic U937 and HL-60 cells. TNF-a and IFN-g, especially, induced apoptosis and differentiation in the treated leukemic cells. Furthermore, antitumor activity of G. lucidum on intraperitioneally implanted Lewis lung carcinoma in syngeneic C57BL/6 mice was investigated. The results showed that GLP significantly increased the lifespan of tumor-implanted mice, when administered intraperioneally alone or in combination with cytotoxic antitumor drugs (adriamycin, fluorouracil, thioguanine, methotrexate, or cisplatin) or a synthetic immunomodulator (imexon). The GLP was not cytotoxic to cultured cells, and the antitumor activity was abolished by pretreatment of mice with cyclosporine. These observations suggest that GLP exerts its antitumor effect mainly through immunopotentiation of the tumor-bearing animals.

http://www.dl.begellhouse.com/journals/708ae68d64b17c52,58cadf0c6c913237,1af485045b17e424.html

Reishi vs. tumors and inflammation

A series of lanostane-type triterpene acids, including eleven lucidenic acids (3, 4, 9, 10, 13–19) and six ganoderic acids (20–22, 24, 26, 27), as well as six sterols (28–33), all isolated from the fruiting bodies of the fungus Ganoderma lucidum, were examined for their inhibitory effects on the induction of Epstein–Barr virus early antigen (EBV-EA) by 12-O-tetradecanoylphorbol-13-acetate (TPA) in Raji cells, a known primary screening test for anti-tumor promoters. All of the compounds tested, except for ganolactone (27) and three sterols (29–31), showed potent inhibitory effects on EBV-EA induction, with IC50 values of 235–370 mol ratio/32 pmol TPA. In addition, nine lucidenic acids (1, 2, 5–8, 11, 12, 18) and four ganoderic acids (20, 23–25) were found to inhibit TPA-induced inflammation (1 μg/ear) in mice, with ID50 values of 0.07–0.39 mg per ear. Further, 20-hydroxylucidenic acid N (18) exhibited inhibitory effects on skin-tumor promotion in an in vivo two-stage mouse-skin carcinogenesis test based on 7,12-dimethylbenz[a]anthracene (DMBA) as initiator, and with TPA as promoter.

http://onlinelibrary.wiley.com/doi/10.1002/cbdv.200790027/full

Reishi vs. cancer

The meta-analysis results showed that patients who had been given G. lucidum alongside with chemo/radiotherapy were more likely to respond positively compared to chemo/radiotherapy alone (RR 1.50; 95% CI 0.90 to 2.51, P = 0.02). G. lucidum treatment alone did not demonstrate the same regression rate as that seen in combined therapy. The results for host immune function indicators suggested that G. lucidum simultaneously increases the percentage of CD3, CD4 and CD8 by 3.91% (95% CI 1.92% to 5.90%, P < 0.01), 3.05% (95% CI 1.00% to 5.11%, P < 0.01) and 2.02% (95% CI 0.21% to 3.84%, P = 0.03), respectively. In addition, leukocyte, NK-cell activity and CD4/CD8 ratio were marginally elevated. Four studies showed that patients in the G. lucidum group had relatively improved quality of life in comparison to controls. One study recorded minimal side effects, including nausea and insomnia. No significant haematological or hepatological toxicity was reported.

Our review did not find sufficient evidence to justify the use of G. lucidum as a first-line treatment for cancer. It remains uncertain whether G. lucidum helps prolong long-term cancer survival. However, G. lucidum could be administered as an alternative adjunct to conventional treatment in consideration of its potential of enhancing tumour response and stimulating host immunity. G. lucidum was generally well tolerated by most participants with only a scattered number of minor adverse events. No major toxicity was observed across the studies. Although there were few reports of harmful effect of G. lucidum, the use of its extract should be judicious, especially after thorough consideration of cost-benefit and patient preference. Future studies should put emphasis on the improvement in methodological quality and further clinical research on the effect of G. lucidum on cancer long-term survival are needed. An update to this review will be performed every two years.

http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007731.pub3/full

Where to buy medicinal mushrooms? Order mushroom extracts from China

What you should know about medicinal mushroom extracts:

– buy only hot water mushroom extracts OR alcohol mushroom extracts
– avoid powdered mushroom because your body will not digest “chitin”
– avoid powdered mushrooms because they almost don’t have any active ingredients
– hot water extraction is the only way for breaking polysaccharides out of indigestible mushroom cells
– seriously, powdered mushrooms are not better than “placebo”
– only extraction provides concentrated polysaccharides
– only extraction provides good concentration of bioavailable ingredients
– read this article about five major medicinal mushrooms: “Immune Modulation From Five Major Mushrooms: Application to Integrative Oncology”
https://ww.ncbi.wnlm.nih.gov/pmc/articles/PMC4684115/

Where to buy good quality medicinal mushrooms extracts?

There are many companies selling “food suplements” with medicinal mushrooms. Unfortunetly they are extremly overpriced and often contain powdered mushrooms instead of mushroom extracts. Many companies sell products that are not better than “placebo”. It’s because your body will not digest chitin from powdered mushrooms.

Fortunetly you can order mushroom extracts from China.

A few months ago I was looking for a good bio-technology company from China. I’ve requested informations from 15-20 sellers available on AliBaba and AliExpress. That’s how I found XI’AN NATE BIOLOGICAL TECHNOLOGY CO.,LTD.

They gave me the answers to all my questions and they had real knowledge about mushroom extracts. That’s why I decided to buy Coriolus Versicolor (Trametes Versicolor) extract from them. I paid via Western Union and a few days later I got my package, via FedEx, without any problems.

http://www.natesw.com/

That’s why I decided to share my knowledge with you and I asked them for actual price list for all medicinal mushrooms extracts.

Prices below are for 200 kgs, but you can order 1 kg too. Of course the price for 1 kg will be higher.

Item name Specifications / Active ingredients Ref.Qty.kg USD/kg FOB
Chaga mushroom extract (from fruiting body) Polysaccharide>40%,triterpene>2%, Betulinic acid >2% 200kg $ 74.0/kg

Polysaccharide>20%,triterpene>6% 200kg $ 132.0/kg
Reishi mushroom spore powder Wall broken ratio>98% 200kg $55.0/kg
Reishi mushroom extract (from fruiting body) Polysaccharide>30%,triterpenoid>2% 200kg $57.0/kg

Polysaccharide>40%,triterpenoid>2% 200kg $70.0/kg
Polysaccharide>10%,triterpenoid>4% 200kg $86.0/kg
Polysaccharide>10%,triterpenoid>8% 200kg $125.0/kg
Cordycep sinensis extract(CS-4 mycelium) Polysaccharide>30%,Adenosine 0.5 200kg $65.0/kg
 Polysaccharide>40%,Adenosine 1.0 200kg $74.0/kg
Cordyceps militaris extract (from fruiting body) Polysaccharide>40%,Adenosine 0.5 200kg $ 73.0/kg

Polysaccharide>50%,Adenosine 1.0 200kg $ 85.0/kg
Polysaccharide>20%,Cordycepin 1.0% 200kg $ 97.0/kg
Polysaccharide>15%,Cordycepin 3.0% 200kg $ 302.0/kg
Lion’s mane mushroom extract (from fruiting body) Polysaccharide>40% 200kg $ 64.0/kg
 Polysaccharide>50% 200kg $ 75.0/kg
Coriolus versicolor / Turkey tail extract Polysaccharide>40% 200kg $ 65.0/kg
 Glycopeptide 30%,protein 10% 200kg $ 86.0/kg
Shiitake mushroom extract (from fruiting body)

Polysaccharide>40% 200kg $54.0/kg
 Polysaccharide>50% 200kg $62.0/kg
Maitake mushroom extract Polysaccharide>40% 200kg $ 67.0/kg
Maitake mushroom extract MD>30%,Protein10% 200kg

$114.0/kg

Agaricus blazei extract Polysaccharide>40% 200kg $ 55.0/kg
Phellinus igniarius extract (from fruiting body)

Polysaccharide>20%,triterpenoid>1% 200kg

$57.0/kg

 Polysaccharide>40%,triterpenoid>2% 200kg

$99.0/kg

Tremella fuciformis extract Polysaccharide>40% 200kg

$65.0/kg

Enoki mushroom extract Polysaccharide>40% 200kg

$67.0/kg

Coprinus comatus extract Polysaccharide>40% 200kg

$65.0/kg

Agrocybe cylindraceaextract Polysaccharide>40% 200kg

$64.0/kg

Antrodia Camphorata extract Polysaccharide>40% 200kg

$83.0/kg

Poria cocos extract

Polysaccharide>40% 200kg

$54.0/kg

Polyporus umbellatus extract Polysaccharide>40% 200kg

$58.0/kg

AHCC

Alpha-glucan>40%

200kg

$89.0/kg

Agaricus bisporus extract Polysaccharide>40%

200kg

$58.0/kg

Chantarelle extract Polysaccharide>40%

200kg

$56.0/kg

Boletus edulis extract Polysaccharide>40%

200kg

$67.0/kg

Alternative HPV treatments / cure research / clinical trials 2018

Photodynamic Therapy

Photodynamic therapy (PDT), sometimes called photochemotherapy, is a form of phototherapy involving light and a photosensitizing chemical substance, used in conjunction with molecular oxygen to elicit cell death (phototoxicity). PDT has proven ability to kill microbial cells, including bacteria, fungi and viruses. PDT is popularly used in treating acne. It is used clinically to treat a wide range of medical conditions, including wet age-related macular degeneration, psoriasis, atherosclerosis and has shown some efficacy in anti-viral treatments, including herpes. It also treats malignant cancers including head and neck, lung, bladder and particular skin. The technology has also been tested for treatment of prostate cancer, both in a dog model and in prostate cancer patients. It is recognised as a treatment strategy that is both minimally invasive and minimally toxic. (Wikipedia)

In case of genital warts / cancer caused by HPV it is possible to use Photodynamic Therapy (PDT) with 5-aminolevulinic acid (ALA). It’s called ALA-PDT.

For more informations check this PDF file, page no. 14 and following pages:
https://www.cdc.gov/std/tg2015/evidence-tables/hpvtableevidence-genitalwarts-2015.pdf

Immunotherapy with Virus Like Particles (VLPs)

Genital warts are caused by infection with human papillomavirus type 6 (HPV6) or less commonly the closely related HPV 11.1,2 While benign, these lesions commonly persist, with less than half of immunocompetent patients resolving infection within six months.3 Despite use of destructive therapies including electrocautery, cryotherapy, or application of podophyllotoxin or trichloroacetic acid, disease recurrence is common.4 However, generation of specific immunity to papillomavirus proteins appears important for clearance, as immunosuppressed individuals with impaired cell mediated immunity clear genital warts more slowly, and more commonly have recurrence after treatment.5

The major papillomavirus protein L1 self assembles into virus like particles, which, together with alum based adjuvants, are the basis of vaccines licensed for use for prevention of HPV infection. L1 virus like particles, in animal models, can induce strong cell mediated immune responses including cytotoxic T-cell responses if delivered without adjuvant. A phase 1 open label safety trial of unadjuvanted HPV6 VLPs (VLP immunotherapy) in patients with treatment refractory genital warts had observed regression of disease that would not have been expected from previous studies of therapy in similar patients.9 Therefore a randomized placebo controlled trial was undertaken to establish whether VLP immunotherapy could reduce the recurrence of genital warts following locally destructive therapy.

Read the whole article:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495719/

Lopimune (Lopinavir/Ritonavir) as a Treatment for HPV-Related Pre-Invasive Cervical Disease

A total of 23 women with HSIL were treated with Lopimune during which time no adverse reactions were reported. A maximum concentration of 10 ng/ml of lopinavir was detected in patient plasma 1 week after starting treatment. HPV was no longer detected in 12/23 (52.2%, 95%CI: 30.6–73.2%). Post-treatment cytology at 12 weeks on women with HSIL, showed 14/22 (63.6%, 95%CI: 40.6–82.8%) had no dysplasia and 4/22 (18.2%, 95%CI: 9.9–65.1%) were now low grade demonstrating a combined positive response in 81.8% of women of which 77.8% was confirmed by histology. These data are supported by colposcopic images, which show regression of cervical lesions.

Read the whole article:
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0147917

Panavir – antiviral medicine from Russia

Panavir – biologically active substance of Panavir is ”GG17” – plant polysaccharide, relating tohexose glycoside class. It main dosage form – intravenous solution 0,004% in 5 ml ampoules (single therapeutic dose). Additional dosage form: rectal suppositories, vaginal suppositories, gel for outward application. Preparation has original pharmacologic property, non-toxic in therapeutic dose (LD50 ~ 3000 therapeutic dose). It is successfully used where ordinary antiviral preparations are not effective or contraindicative or have unsatisfactorily effect: chronic tick-borne encephalitis, ophthalmoherpes, herpes zoster (shingles), cytomegalovirus, Epstein-Barr virus, Human papilloma virus. Now Panavir tests for treatment chronic hepatitis B and C.

Read the whole article:
http://poi555.com/2018/01/panavir-from-russia-alternative-treatment-for-hpv-and-genital-warts/

Combined therapy: remove genital warts + use Inosine Pranobex

This study evaluates the effectiveness of immunomodulating drug isoprinosine in a comprehensive treatment of genital warts in men. Most of the patients were aged 20-30 years. The combination therapy was found to have long term effectiveness. In the group of patients undergoing only destructive methods of treatment relapse after 8 month follow-up was diagnosed in 32% and in patients of the combination therapy group (destruction plus isoprinosine) – in 7% of patients. The pharmacological action of the drug (immunostimulating, antiviral) and the effectiveness of its combination with destructive therapies justify the use of inosine pranobex (isoprinosine) both in the complex therapy of genital warts and for the prevention of the disease recurrence.

Source

Reishi (Ganoderma Lucidum) vs. cancer

The mushroom Ganoderma lucidum (G. lucidum) has been used for centuries in Asian countries to treat various diseases and to promote health and longevity. Clinical studies have shown beneficial effects of G. lucidum as an alternative adjuvant therapy in cancer patients without obvious toxicity. G. lucidum polysaccharides (GLP) is the main bioactive component in the water soluble extracts of this mushroom. Evidence from in vitro and in vivo studies has demonstrated that GLP possesses potential anticancer activity through immunomodulatory, anti-proliferative, pro-apoptotic, anti-metastatic and anti-angiogenic effects. Here, we briefly summarize these anticancer effects of GLP and the underlying mechanisms.

STUDY 1:

Consumption of reishi mushroom has been reported to prevent colon carcinogenesis in rodents, although the underlying mechanisms remain unclear. To investigate this effect, rats were fed a high-fat diet supplemented with 5% water extract from either the reishi mushroom (Ganoderma lingzhi) (WGL) or the auto-digested reishi G. lingzhi (AWGL) for three weeks. Both extracts markedly reduced fecal secondary bile acids, such as lithocholic acid and deoxycholic acid (colon carcinogens). These extracts reduced the numbers of Clostridium coccoides and Clostridium leptum (secondary bile acids-producing bacteria) in a per g of cecal digesta. Fecal mucins and cecal propionate were significantly elevated by both extracts, and fecal IgA was significantly elevated by WGL, but not by AWGL. These results suggest that the reishi extracts have an impact on colon luminal health by modulating secondary bile acids, microflora, mucins, and propionate that related to colon cancer.

https://www.ncbi.nlm.nih.gov/pubmed/28661219

STUDY 2:

The medical mushroom Ganoderma lucidum (Reishi), a traditional Chinese medicine, has exhibited a promising anti-cancer effect. However, the molecular mechanism of its action on cancer cells remains unclear. Aberrant activation of Wnt/β-catenin signaling pathway is the cause of many types of cancer, including breast cancer. Here we investigated the effect of Reishi on Wnt/β-catenin signaling pathway and elucidated the molecular mechanism of its function in inhibiting breast cancer cells. We found that Reishi blocked Wnt/β-catenin signaling through inhibiting the phosphorylation of Wnt co-receptor LRP6. In human (MDA-MB-231) and mouse (4T1) breast cancer cell lines, Reishi significantly decreased the phosphorylation of LRP6 and suppressed Wnt3a-activated Wnt target gene Axin2 expression. Administration of Reishi inhibited Wnt-induced hyper-proliferation of breast cancer cells and MDA-MB-231 cell migration. Our results provide evidence that Reishi suppresses breast cancer cell growth and migration through inhibiting Wnt/β-catenin signaling, indicating that Reishi may be a potential natural inhibitor for breast cancer.

https://www.ncbi.nlm.nih.gov/pubmed/28427938

STUDY 3:

The present study investigated the anticancer effects and potential mechanisms of BSGLWE on colorectal cancer in vivo and in vitro. Our results showed that BSGLWE significantly inhibited colorectal cancer HCT116 cell viability in a time- and dose-dependent manner. Flow cytometry analysis indicated that BSGLWE disrupted cell cycle progression at G2/M phase via downregulation of cyclin B1 and cyclin A2, and upregulation of P21 at mRNA levels. Moreover, BSGLWE induced apoptosis by decreasing Bcl-2 and survivin at mRNA levels, and reduced Bcl-2, PARP, pro-caspase-3 and pro-caspase-9 at protein levels. Furthermore, BSGLWE suppressed tumor growth in vivo by regulating the expression of genes and proteins associated with cell cycle and apoptosis, which was further confirmed by a reduction of Ki67, PCNA, and Bcl-2 expression as determined by immunohistochemistry staining. NSAID activated gene-1 (NAG-1), a pro-apoptotic gene, was significantly upregulated in vivo and in vitro upon BSGLWE treatment at both mRNA and protein levels. In addition, the relative amounts of secreted NAG-1 in cell culture medium or serum of nude mice were all upregulated upon BSGLWE treatments, suggesting a role of NAG-1 in BSGLWE-induced anticolorectal cancer activity. This is the first study to show that BSGLWE inhibits colorectal cancer carcinogenesis through regulating genes responsible for cell proliferation, cell cycle and apoptosis cascades. These findings indicate that BSGLWE possesses chemopreventive potential in colorectal cancer which may serve as a promising anticancer agent for clinical applications.

https://www.ncbi.nlm.nih.gov/pubmed/28358412

STUDY 4:

The aim of this study is to investigate the anti-inflammatory, anticancer and anti-metastatic activities of Ganoderma lucidum extracts in melanoma and triple-negative breast cancer cells. Ganoderma lucidum extracts were prepared by using common organic solvents; MDA-MB 231 and B16-F10 cell lines were adopted as cellular models for triple-negative breast cancer and melanoma and characterized for cell viability, wound-healing assay and measurement of cytokines secreted by cancer cells under pro-inflammatory conditions (incubation with lipopolysaccharide, LPS) and pretreatment with Ganoderma lucidum extract at different concentrations. Our study demonstrates, for the first time, how Ganoderma lucidum extracts can significantly inhibit the release of IL-8, IL-6, MMP-2 and MMP-9 in cancer cells under pro-inflammatory condition. Interestingly, Ganoderma lucidum extracts significantly also decrease the viability of both cancer cells in a time- and concentration-dependent manner, with abilities to reduce cell migration over time, which is correlated with a lower release of matrix metalloproteases. Taken together, these results indicate the possible use of Ganoderma lucidum extract for the therapeutic management of melanoma and human triple-negative breast cancer.

https://www.ncbi.nlm.nih.gov/pubmed/28264501

STUDY 5:

G. lucidum polysaccharides – mainly β-glucans and heteroglycans – have numerous biological properties such as antitumour and immunomodulatory activities. This report shows, by gene expression analyses and bioenergetic assays, immunomodulatory properties and capacity to improve glucose metabolism of a water-soluble heteroglycan extracted from mycelium of an Italian isolate of G. lucidum. The findings suggest the use of the heteroglycan as probiotic or ingredient in functional foods, being easy to produce and disperse in a food matrix thanks to its water-solubility. Heteroglycan could exert protective effects in pro-inflammatory conditions and benefits for people characterised by suppressed immune response.

https://www.ncbi.nlm.nih.gov/pubmed/28105862